{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:57:00Z","timestamp":1779886620089,"version":"3.53.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.beha.2021.101333","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:24:10Z","timestamp":1635506650000},"page":"101333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Changing trends in the therapy of acute myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Jacob M.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2021.101333_bib1","unstructured":"American Cancer Society. Key Statistics for Acute Myeloid Leukemia. Available at: https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html."},{"key":"10.1016\/j.beha.2021.101333_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5030033","article-title":"Acute myeloid leukemia: a concise review","volume":"5","author":"Saultz","year":"2016","journal-title":"J Clin Med"},{"key":"10.1016\/j.beha.2021.101333_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101333_bib4","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.beha.2019.101094","article-title":"Will new agents impact survival in AML?","volume":"32","author":"Rowe","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2021.101333_bib5","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.beha.2021.101333_bib6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","article-title":"Acute myeloid leukemia: historical perspective and progress in research and therapy over 5 decades","volume":"21","author":"Kantarjian","year":"2021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2021.101333_bib7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2019001728","article-title":"Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period","volume":"134","author":"Juliusson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101333_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.V46.2.209.209","article-title":"Platelet storage at 22 degrees C: role of gas transport across plastic containers in maintenance of viability","volume":"46","author":"Murphy","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101333_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.16708","article-title":"Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?","volume":"190","author":"Loke","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2021.101333_bib11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJM199104113241501","article-title":"A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV Study Group","volume":"324","author":"Schmidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41375-020-01058-4","article-title":"Evolving treatment patterns and outcomes in older patients (\u226560 years) with AML: changing everything to change nothing?","volume":"35","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2021.101333_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.beha.2021.101333_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Lowenberg","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib16","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101333_bib17","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/cancers12010059","article-title":"Is there still a role for autologous stem cell transplantation for the treatment of acute myeloid leukemia?","volume":"12","author":"Ferrara","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.beha.2021.101333_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant : J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.beha.2021.101333_bib20","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.bbmt.2019.08.012","article-title":"Comparison of high doses of total body irradiation in myeloablative conditioning before hematopoietic cell transplantation. Biology of blood and marrow transplantation","volume":"25","author":"Sabloff","year":"2019","journal-title":"J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.beha.2021.101333_bib21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101333_bib22","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101333_bib23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or thiotepa, busulfan, and fludarabine (TBF): a retrospective study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:13Z","timestamp":1761498373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521692621000980"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101333","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing trends in the therapy of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101333"}}